Susan Sloan

Susan Sloan has a strong background in translational medicine and research, particularly in the development of protein therapeutics. Susan started their career at MassBiologics in 2004 as a Research Scientist II, where they contributed to preclinical discovery efforts for monoclonal antibody projects. Susan later became a Director, responsible for assay development and qualification activities to support clinical development. Susan also provided input on various aspects of drug development, such as target selection and validation, toxicology study design, reference standard characterization, stability testing strategy, and in vitro and in vivo assays. From 2009 to 2013, they served as a Senior Director at MassBiologics.

In 2013, Susan joined Visterra Inc. as a Senior Director of Translational Development. In this role, they led the strategy and operations for the development of drug candidates and served as a critical link between non-clinical, research, clinical, and regulatory teams. Susan oversaw a team of scientists responsible for the design and conduct of translational medicine and research studies, including clinical assays and pharmacokinetic/pharmacodynamic studies. Susan also managed nonclinical studies, such as mechanism of action, efficacy, GLP toxicology, and pharmacokinetic/pharmacodynamic studies to support product development.

Over the years, Susan progressed at Visterra Inc. and held the position of Executive Director, Translational from 2019 onwards. Currently, they serve as the VP of Nonclinical Development, further advancing their responsibilities within the company.

Susan Sloan completed their Bachelor of Science degree in Biology at Penn State University from 1994 to 1998. Susan then pursued further education at Tufts University School of Medicine, specializing in the Graduate School of Biomedical Sciences, where they obtained their PhD from 1998 to 2004.